DE69935599D1 - Modifizierte hcv peptid-impfstoffe - Google Patents

Modifizierte hcv peptid-impfstoffe

Info

Publication number
DE69935599D1
DE69935599D1 DE69935599T DE69935599T DE69935599D1 DE 69935599 D1 DE69935599 D1 DE 69935599D1 DE 69935599 T DE69935599 T DE 69935599T DE 69935599 T DE69935599 T DE 69935599T DE 69935599 D1 DE69935599 D1 DE 69935599D1
Authority
DE
Germany
Prior art keywords
subject
amino acid
core polypeptide
hcv core
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69935599T
Other languages
English (en)
Other versions
DE69935599T2 (de
Inventor
Jay A Berzofsky
Pablo Sarobe
Stephen M Feinstone
Marian E Major
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69935599D1 publication Critical patent/DE69935599D1/de
Application granted granted Critical
Publication of DE69935599T2 publication Critical patent/DE69935599T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69935599T 1998-08-21 1999-08-17 Modifizierte hcv peptid-impfstoffe Expired - Lifetime DE69935599T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9744698P 1998-08-21 1998-08-21
US97446P 1998-08-21
PCT/US1999/018674 WO2000011186A1 (en) 1998-08-21 1999-08-17 Modified hcv peptide vaccines

Publications (2)

Publication Number Publication Date
DE69935599D1 true DE69935599D1 (de) 2007-05-03
DE69935599T2 DE69935599T2 (de) 2007-11-29

Family

ID=22263394

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69935599T Expired - Lifetime DE69935599T2 (de) 1998-08-21 1999-08-17 Modifizierte hcv peptid-impfstoffe

Country Status (6)

Country Link
US (3) US6685944B1 (de)
EP (1) EP1105496B1 (de)
AT (1) ATE357526T1 (de)
AU (1) AU5776799A (de)
DE (1) DE69935599T2 (de)
WO (1) WO2000011186A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
CN1822856B (zh) 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
US20080112977A1 (en) * 2004-07-03 2008-05-15 Mogam Biotechnology Research Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof
WO2006134280A2 (fr) * 2005-06-17 2006-12-21 Transgene Sequences nucleotidiques mutees du virus de l'hepatite c
FR2887260A1 (fr) * 2005-06-17 2006-12-22 Centre Nat Rech Scient Sequences nucleotidiques mutees du virus de l'hepatite c
WO2011001897A1 (ja) * 2009-06-30 2011-01-06 明治製菓株式会社 難治性のｃ型慢性肝炎の治療のための薬剤及び方法
JP7068323B2 (ja) * 2017-02-02 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー 少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0992580T3 (da) 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
WO1995027733A1 (en) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Department Of Health & Human Services Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DE69723434T2 (de) * 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines

Also Published As

Publication number Publication date
ATE357526T1 (de) 2007-04-15
US7074410B2 (en) 2006-07-11
WO2000011186A9 (en) 2002-08-22
US20050129705A1 (en) 2005-06-16
US6685944B1 (en) 2004-02-03
WO2000011186A1 (en) 2000-03-02
US7341726B2 (en) 2008-03-11
DE69935599T2 (de) 2007-11-29
EP1105496B1 (de) 2007-03-21
AU5776799A (en) 2000-03-14
EP1105496A1 (de) 2001-06-13
US20060275322A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
DE69838143D1 (de) Antimikrobielle peptide
EP2258383A3 (de) Von der Telomerase abgeleitete antigene Peptide
CA2263889A1 (en) P-selectin ligand proteins
DE60035419D1 (de) Antigene peptide aus neisseria
AU3406595A (en) Nucleotide and amino acid sequences of the envelope 1 and core genes of hepatitis c virus
ATE357526T1 (de) Modifizierte hcv peptid-impfstoffe
NZ506748A (en) Nucleic acids encoding a GFR alpha 3 polypeptide; host cell and vectors for production of the GRF alpha 3 protein and an assay for detecting GRFalpha 3 production
ATE282634T1 (de) Chaperonin 10
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
NO20011263D0 (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
NO20006456L (no) En mutant human hepatitt B viral stamme og anvendelser derav
WO2001074847A3 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
WO1999043834A3 (en) P-selectin ligand protein, including tetrameric fusion proteins
SE0002738D0 (sv) Electric actuator
EP1295943A4 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
WO2003023006A3 (en) Hemocyanin nucleic acids and polypeptides and related vectors, fusion proteins, conjugates, cells and methods of use
HUP0001462A2 (en) Human toll-like receptor proteins, related reagents and methods
WO2002026978A1 (fr) Nouvelles proteines, genes codant ces proteines et leur procede d'utilisation
NZ509284A (en) Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call
NZ606260A (en) Novel polypeptides involved in immune response

Legal Events

Date Code Title Description
8364 No opposition during term of opposition